Welcome, Guest. Please login or register.
April 05, 2020, 08:10:48 pm

Login with username, password and session length


Members
Stats
  • Total Posts: 753343
  • Total Topics: 63524
  • Online Today: 306
  • Online Ever: 4912
  • (November 13, 2019, 02:56:14 am)
Users Online
Users: 4
Guests: 161
Total: 165

Welcome


Welcome to the POZ Community Forums, a round-the-clock discussion area for people with HIV/AIDS, their friends/family/caregivers, and others concerned about HIV/AIDS.  Click on the links below to browse our various forums; scroll down for a glance at the most recent posts; or join in the conversation yourself by registering on the left side of this page.

Privacy Warning:  Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If you are HIV positive and disclose this in our forums, then it is almost the same thing as telling the whole world (or at least the World Wide Web). If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.

  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.

  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.

  • Forums members must behave at all times with respect and honesty. Posting guidelines, including time-out and banning policies, have been established by the moderators of these forums. Click here for “Am I Infected?” posting guidelines. Click here for posting guidelines pertaining to all other POZ community forums.

  • We ask all forums members to provide references for health/medical/scientific information they provide, when it is not a personal experience being discussed. Please provide hyperlinks with full URLs or full citations of published works not available via the Internet. Additionally, all forums members must post information which are true and correct to their knowledge.

  • Product advertisement—including links; banners; editorial content; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from POZ.

To change forums navigation language settings, click here (members only), Register now

Para cambiar sus preferencias de los foros en español, haz clic aquí (sólo miembros), Regístrate ahora

Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: Trial: Cabenuva injectable (cabotegravir/rilpivirine) for Those Nonadherent to Daily Meds  (Read 1141 times)

0 Members and 1 Guest are viewing this topic.

Offline Jim Allen

  • Administrator
  • Member
  • Posts: 15,181
  • Twitter @JimAllenDublin
    • HIV Lessons
Will be interesting to see the results, hopefully a better fit for those who have adherence barriers.

https://www.poz.com/article/trial-launches-longacting-hiv-regimen-nonadherent-daily-meds

In short:
Quote
Trial Launches of Long-Acting HIV Regimen for Those Nonadherent to Daily Meds

The trial will investigate whether injections of long-acting cabotegravir and rilpivirine yield a superior rate of viral suppression.

The National Institutes of Health (NIH) has launched a trial of long-acting injectable HIV treatment given every four weeks for those who have not adhered well to a daily oral antiretroviral (ARV) regimen. The study will investigate whether randomizing such individuals to receive the injectable treatment will yield a higher rate of viral suppression after one year, compared with randomizing individuals to stay on daily oral treatment.

The injectable regimen includes long-acting formulations of ViiV Healthcare’s cabotegravir and Janssen’s rilpivirine. In April, ViiV applied for Food and Drug Administration (FDA) approval of the injectable regimen, so the agency will likely make a decision by the end of 2019.

Whether people with HIV will prefer to go to a clinic for a shot every month instead of taking daily ARV pills is an open question. However, this regimen may prove a good fit for those who adhere poorly to traditional oral regimens—hence, this new trial.
HIV 101 - Everything you need to know
HIV 101
Transmission and Risks:
HIV Transmission and Risks
Read more about Testing here:
HIV Testing
Read about Treatment-as-Prevention (TasP) here:
HIV TasP
You can read about HIV prevention here:
HIV prevention
Read about PEP and PrEP here
PEP and PrEP

Offline Jim Allen

  • Administrator
  • Member
  • Posts: 15,181
  • Twitter @JimAllenDublin
    • HIV Lessons
Long-Acting HIV Regimen Cabenuva Is Effective With Dosing Every 8 Weeks.

Now if they can get this down to 1 shot every 6 months or home injectable I might consider it myself.

https://www.poz.com/article/longacting-hiv-regimen-cabenuva-effective-dosing-every-8-weeks

In Short:
Quote
The experimental long-acting injectable antiretroviral (ARV) regimen Cabenuva (cabotegravir/rilpivirine) suppresses HIV as effectively when given only every eight weeks as when given every four weeks and is safe and well tolerated. Furthermore, the recent large trial that yielded these findings also found that almost all participants favored receiving injections only every two months over doing so monthly or taking daily oral antiretrovirals.

If approved, Cabenuva would be the first long-acting injectable ARV regimen. The randomized controlled Phase III ATLAS and FLAIR studies demonstrated that Cabenuva administered every four weeks suppresses HIV as effectively as daily oral triple ARV treatment for people who entered the study with a fully suppressed viral load thanks to oral therapy.

In December, the Food and Drug Administration (FDA) declined ViiV Healthcare’s application for approval of Cabenuva given every four weeks as treatment for people who have a fully suppressed viral load and who transition onto the long-acting regimen from a stable daily oral regimen. It appears that this decline would amount only to a delay, as the FDA expressed concerns about the manufacturing process for Cabenuva. ViiV has stated that it is working with the FDA to address those concerns and bring the regimen to market.
HIV 101 - Everything you need to know
HIV 101
Transmission and Risks:
HIV Transmission and Risks
Read more about Testing here:
HIV Testing
Read about Treatment-as-Prevention (TasP) here:
HIV TasP
You can read about HIV prevention here:
HIV prevention
Read about PEP and PrEP here
PEP and PrEP

Offline Loa111

  • Member
  • Posts: 221
Interesting...even if home injectable every 2 months with a piece of kit like diabetics have...that would be amazing. We could almost forget we’ve got this health condition.

Offline harleymc

  • Member
  • Posts: 1,361
Every second month is starting to be attractive.

Once a month would have been difficult to arrange time off work.

Offline Jim Allen

  • Administrator
  • Member
  • Posts: 15,181
  • Twitter @JimAllenDublin
    • HIV Lessons
Update:

https://www.poz.com/article/canada-first-approve-longacting-hiv-regimen-cabenuva

Quote
Canada has become the first nation in the world to approve ViiV Healthcare’s monthly long-acting injectable antiretroviral (ARV) regimen Cabenuva (cabotegravir/rilpivirine)—the first complete regimen for treating the virus that does not require daily pills.

In late December, the Food and Drug Administration (FDA) held up approval of the regimen, citing concerns over its manufacturing process. In turn, ViiV indicated it was working closely with the FDA to address those concerns and ultimately bring Cabenuva to market in the United States.

ViiV first applied for FDA approval of Cabenuva in April 2019.

Health Canada approved Cabenuva for people with HIV to swith to if they have a fully suppressed viral load (below 50) thanks to a standard oral ARV regimen.
HIV 101 - Everything you need to know
HIV 101
Transmission and Risks:
HIV Transmission and Risks
Read more about Testing here:
HIV Testing
Read about Treatment-as-Prevention (TasP) here:
HIV TasP
You can read about HIV prevention here:
HIV prevention
Read about PEP and PrEP here
PEP and PrEP

Offline wardp

  • Member
  • Posts: 156
Just for future reference  could this be  taking if you  didn't take your omeprazole the same day as the injection or is the injection still classed as having an interaction the same as the tablet that needs stomach acid?
Diagnosed 20,July 2017. Cd4 289, 21% vld .3,462 Started atripla 4 Aug 2017 5oct 2017 cd4 384 21%, vl ud less than 20. Switch to complera 4 Nov 2017 switched to stribild 15 the Nov. Switched to truvada efavirence 200mgx2 14 Dec 2017, 2 Feb 2018, us cd4  466, 25%  CD 8 ,595, 32%..1 may 2018
switched  to instgra truvada.7th june switched to truvada  nevirapine stavudine. .21 june switched to truvada nevirapine. X 2 a day...9 aug 2018 ud. 2n Nov 2018 CD 4. 455..22.70% 13th Nov switched  to lamivir and nevirapine  due to kidney issues...jan 10,2019 UD..may 13 2019 ud  cd4 482 28% 14th nov 2019 ud. Cd4 414 .27% cd8 444 29%


 


Terms of Membership for these forums
 

© 2020 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.